Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
We have examined the effects of commonly used chemotherapeutic agents on human colon cancer cell lines in which the p53 pathway has been specifically disrupted by targeted homologous recombination. We found that p53 had profound effects on drug responses, and these effects varied dramatically depending on the drug. The p53-deficient cells were sensitized to the effects of DNA-damaging agents as a result of the failure to induce expression of the cyclin-dependent kinase inhibitor p21. In contrast, p53 disruption rendered cells strikingly resistant to the effects of the antimetabolite 5-fluorouracil (5-FU), the mainstay of adjuvant therapy for colorectal cancer. The effects on 5-FU sensitivity were observed both in vitro and in vivo, were independent of p21, and appeared to be the result of perturbations in RNA, rather than DNA, metabolism. These results have significant implications for future efforts to maximize therapeutic efficacy in patients with defined genetic alterations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some conventional chemotherapeutic drugs depend on the activation of p53 for their efficacy.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Comparing p53-proficient and -deficient HCT116 cells, such a dependency was found in particular for 5-fluorouracil (5-FU)44.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
In the citing paper
“A series of clinical studies have confirmed that CRC patients with wild-type P53 can benefit from 5-FU, and CRC patients with mutant P53 have a poor prognosis when receiving adjuvant chemotherapy [258,259,260].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [259]
In the citing paper
“A series of clinical studies have confirmed that CRC patients with wild-type P53 can benefit from 5-FU, and CRC patients with mutant P53 have a poor prognosis when receiving adjuvant chemotherapy [258,259,260].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [259]
In the citing paper
“On the other hand, the same report showed that p53-deficient cells displayed a higher sensitivity towards topoisomerase inhibitors such as Adriamycin.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Green, D. R., & Reed, J. C. (1998) · Science · doi:10.1126/science.281.5381.1309 · Cited by 8,965
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803 · cited 4×
“We attribute this difference to the small amount of p53independent p21 induction following DNA damage that occurs after adriamycin treatment of p53-deficient cells (not shown), similar to that observed after γ-irradiation (14).”
BackgroundMethodInfluentialSelf-citationA model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
Self-citationKo, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344 · cited 1×
“Introduction The p53 gene is inactivated in the majority of human cancers, resulting in profound effects on cell birth and death processes (1, 2).”
BackgroundMice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
p53 Status and the Efficacy of Cancer Therapy in Vivo
Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T. (1994) · Science · doi:10.1126/science.7973635 · Cited by 1,469 · cited 1×
“with mouse cells, for example, have provided unequivocal evidence of drug resistance after p53 inactivation (9, 10), but the extrapolation of these results to humans is far from straightforward.”
BackgroundApoptosis in cancer therapy: Crossing the threshold
Fisher, D. E. (1994) · Cell · doi:10.1016/0092-8674(94)90518-5 · Cited by 1,315
Is a p53-Regulated Inhibitor of G2/M Progression
Hermeking, H., Lengauer, C., Polyak, K., He, T.-C., Zhang, L., Thiagalingam, S., Kinzler, K. W., & Vogelstein, B. (1997) · Molecular Cell · doi:10.1016/s1097-2765(00)80002-7 · Cited by 1,251 · cited 1×
“The checkpoint function of p53 is mediated by the genes it transcriptionally regulates, including p21 (14, 15, 16) and 14-3-3σ (28), and keeps cells from progressing from G1 to S or G2 to M after DNA damage.”
BackgroundSelf-citationRadiation-induced cell cycle arrest compromised by p21 deficiency
Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., & Hannon, G. J. (1995) · Nature · doi:10.1038/377552a0 · Cited by 1,242
Research works printed but not linked: 6
- Hawkins, 1996, Cancer Res, 56, 892
- O’Connor, 1997, Cancer Res, 57, 4285
- Waldman, 1995, Cancer Res, 55, 5187
- Geoffroy, 1994, Oncol Res, 6, 581
- Wyllie, 1997, Eur J Cell Biol, 73, 189
- Cory, 1979, Cancer Res, 39, 4905
Cited by
Items 901–1,000 of 1,000
Sonkaew, S., Duangthim, N., Lomphithak, T., Sae-Fung, A., Nitsakulthong, C., Duangbupha, J., Sasano, H., Choksi, S., Liu, Z.-G., & Jitkaew, S. (2026) · APOPTOSIS · doi:10.1007/s10495-025-02219-5 · Cited by 5
A phenocopy signature of TP53 loss predicts response to chemotherapy
Bakhtiar, H., Sharifi, M. N., Helzer, K. T., Shi, Y., Bootsma, M. L., Shang, T. A., Chrostek, M. R., Berg, T. J., Callahan, S. C., Carreno, V., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00722-7 · Cited by 5
“In preclinical studies, p53 protein loss of function has a profound impact on cellular responses to DNA-damaging agents including cytotoxic chemotherapies and radiation 9 – 11 , leading to the hypothesis that TP53 alterations may serve as a biomarker for sensitivity to cytotoxic che-motherapies.”
BackgroundLu, Y. W., Zhang, Z., Yan, Z., Chen, L., Deng, W., Lotze, M. T., Wang, Z., Lin, X., & Li, L. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0863-1 · Cited by 3
Hashimoto, Y., Ueda, K., Minami, K., & Watatani, M. (2001) · International Journal of Clinical Oncology · doi:10.1007/pl00012089 · Cited by 3
“In our study, the two cell lines without p53 mutations were more sensitive to 5-FU than the other four cell lines with p53 mutations when the cells were exposed to 5-FU for 24h. Bunz et al.35 analyzed the importance of p53 status in the response of human colorectal tumor cells to different chemotherapeutic agents, inc…”
BackgroundCell Cycle and Factors Involved in Inhibition or Progression of Breast Cancer
Ali, S. Y., Dar, M. I., Rather, R. A., & Afroze, D. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.92576 · Cited by 3
Fang, J., Wang, Y., Wang, Z., Xie, T., Yan, F., Wang, L., Hua, J., Wang, F., Fu, Z., & Ye, Z. (2020) · Translational Cancer Research · doi:10.21037/tcr-19-975 · Cited by 3
“Thus, exploring strategies to enhance the function of p53 is important for reversing CDDP resistance (17,18).”
BackgroundPrasad, S. B. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99883-3.00015-9 · Cited by 7
Expression of p53 as a biomarker in determining response to apatinib for advanced gastric cancer
Qiu, Z., Qin, R., Zhang, Z., Zhang, T., Zhang, Z., Qiao, C., Xi, Y., Tian, G., & Wang, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1203980 · Cited by 4
“It has been demonstrated that p53 expression is a predictive factor for platinum resistance, and platinfree combinations can be used in tumors with p53 overexpression (21, 22).”
BackgroundKakafika, M. G., Lyta, A., Gavriilidis, G. I., Tsiftsoglou, S. A., Miliotou, Α. N., Pappas, I. S., Vizirianakis, I. S., Papadopoulou, L. C., & Tsiftsoglou, A. S. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5630 · Cited by 3
“Considering that the HCT‑116 (‑/‑p53) cells are more likely to be glycolytic, the lack of full‑length p53 protein affected the effectiveness of IM and DCA, since these cells were revealed to be less susceptible compared with HCT‑116 (+/+p53) cells as previously proposed (58).”
BackgroundResultTumour site, sex, and survival in colorectal cancer
Iacopetta, B. J., & Elsaleh, H. (2000) · The Lancet · doi:10.1016/s0140-6736(05)73440-1 · Cited by 3
Seo, E. Y. (2013) · Journal of Nutrition and Health · doi:10.4163/jnh.2013.46.6.503 · Cited by 3
Role of Leptomycin in p53 Induced Apoptosis
Ramakrishna, S. C. (2013) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000203 · Cited by 3
Deficiency of Bloom syndrome helicase activity is radiomimetic
Horowitz, D. P., Topaloglu, Ö., Zhang, Y., & Bunz, F. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.11.6779 · Cited by 3
Self-citationTherapeutic Strategies Based on Pharmacological Modulation of p53 Pathway
Gudkov, A. V. (2005) · Springer eBooks · doi:10.1007/0-387-30127-5_10 · Cited by 3
“This was shown to be true in several tumor cell models in which inactivation of p53 function has no effect on radio sensitivity (Brachman et al., 1993; Slichenmyer et al., 1993; Bunz et al., 1999; Roninson et al., 2001).”
BackgroundHypoxia signalling in tumour angiogenesis
Knies, U. E., & Harris, A. L. (2000) · Emerging Therapeutic Targets · doi:10.1517/14728222.4.3.361 · Cited by 3
“However, although it has been observed that inactivation of p53 renders many tumour cells resistant to radio- and chemotherapy, the outcome of cancer treatment appears to depend on the drug that is used, the concentration of the drug and the exact site of the p53 mutation [69,70].”
BackgroundKamoshida, S., Matsuoka, H., Matsuyama, A., Shimomura, R., MARUTA, M., & Tsutsumi, Y. (2003) · Annals of Cancer Research and Therapy · doi:10.4993/acrt1992.11.73 · Cited by 3
Prognostic and Predictive Biomarkers for Colorectal Cancer
Manne, U., Putcha, B. K., Samuel, T., & Srivastava, S. (2017) · Wiley eBooks · doi:10.1002/9781118468869.ch13 · Cited by 3
Sailo, B. L., Vishwa, R., Girisa, S., Aswani, B. S., Abbas, M., Alqahtani, M. S., Almubarak, H. A., Hegde, M., & Kunnumakkara, A. B. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266319955241224073611 · Cited by 3
The influence of p53 status on the cytotoxicity of fluorinated pyrimidine L-nucleosides
Murray, V., Taylor, C. B., Gero, A. M., & Lutze-Mann, L. H. (2015) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.08.010 · Cited by 2
Huang, Z., Luo, S., Wang, Z., Zhang, Z., Jiang, B., Nie, Q. H., & Zhang, J. (2026) · eLife · doi:10.7554/elife.100623.4 · Cited by 5
Mutant p53 Reactivation as a Novel Strategy for Cancer Therapy
Selivanova, G., Bykov, V. J. N., & Wiman, K. G. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_18 · Cited by 3
“cisplatin or 5fluorouracil, activate wild type p53-mediated apoptotic pathways (O'Connor et al. 1997; Bunz et al. 1999; Lai et al. 2000; Lane 2004).”
BackgroundRegunath, K., Fomin, V., Liu, Z., Wang, P., Hoque, M., Tian, B., Rabadán, R., & Prives, C. L. (2024) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-23-0295 · Cited by 2
Puangpraphant, S. (2012) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign) · Cited by 2
Functional p53 is required for rapid restoration of daunorubicin-induced lesions of the spleen
Herfindal, L., Myhren, L. E., Gjertsen, B. T., Døskeland, S. O., & Gausdal, G. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-341 · Cited by 2
“The efficacy of this therapy approach is debated [26], and the response apparently varies between drugs [27].”
BackgroundPredictive values of sex and tumour site for survival benefit from 5FU in colorectal cancer
Iacopetta, B. M. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600279 · Cited by 2
“The molecular features associated with response to 5FU remain to be fully characterized, however both preclinical (Bunz et al, 1999) and clinical (Ahnen et al, 1998; Elsaleh et al, 2001) studies have demonstrated a requirement for normal TP53.”
BackgroundMultidrug resistance in solid tumours
Nicolantonio, F. D. (2004) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 3
Investigating the effect of paralogs on microarray gene-set analysis
Faure, A. J., Seoighe, C., & Mulder, N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-29 · Cited by 1
“[54], which seem to corroborate this result, show that the presence of mutations affecting p53 in human cancer cells renders them resistant to certain drugs used in cancer therapy.”
Fernandes, Q., Inchakalody, V. P., Mestiri, S., Bedhiafi, T., Hydrose, S., Bashraheel, S. S., Merhi, M., Dermime, S., & Moustafa, A. A. (2025) · Cancer Reports · doi:10.1002/cnr2.70197 · Cited by 3
Identification and characterization of BRAF⇔TP53 interactions in melanoma
O’Toole, K. T., Martinez, A., Murphy, B., Fort, G., Al-Sudani, F., Prokofyeva, A., Boggaram, S. S., Smith, E. A., Paine, E. L., Baral, D., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117078 · Cited by 2
Yang, Z., Huang, D., Fang, L., Feng, X., Liu, H., Wang, L., & Wang, J. (2015) · Journal of Cancer Therapy · doi:10.4236/jct.2015.65048 · Cited by 1
“Cells with p53 mutations are less sensitive to 5-FU than cells with wild-type 5-FU [18].”
BackgroundChrisanthar, R. (2009) · NVA (Nasjonalt vitenarkiv) · Cited by 1
Tubal Precursor Lesions for High-Grade Serous Ovarian Carcinoma
Meleis, M. H., & El-Agwany, A. S. (2015) · Indian Journal of Gynecologic Oncology · doi:10.1007/s40944-015-0031-3 · Cited by 1
Apoptosis in Carcinogenesis and Chemotherapy – Esophageal Cancer
Li, Y., & Martin, R. C. G. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9597-9_6 · Cited by 1
UHPLC-HRMS-Based Analysis of S-Hydroxymethyl-Glutathione, GSH, and GSSG in Human Cells
Monge, M. E., Martinefski, M., Bollini, M., & Pontel, L. B. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3247-5_10 · Cited by 1
Jafari, Z., Javadirad, S.-M., & Rouholamini, S. E. Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-10452-w · Cited by 1
Evaluating the Importance of Apoptosis and Other Determinants of Cell Death and Survival
Wouters, B. G., & Chiu, R. K. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-221-2_3 · Cited by 1
“The relationship between treatment dose and clonogenic survival established in vitro has successfully predicted the doses required to cure transplanted tumors in vivo even when rates of apoptosis do not correlate (18, 76 ,77).”
BackgroundMécanismes de résistance à la chimiothérapie
Campone, M., Bourbouloux, E., Berton-Rigaud, D., Pourhiet, A. L., Sadot, S., Chatellier, T., & Frenel, J. (2007) · Springer eBooks · doi:10.1007/978-2-287-72615-6_14 · Cited by 1
Danesi, R., Paolo, A. D., Bocci, G., Crea, F., & Tacca, M. D. (2008) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2008.06.021 · Cited by 1
Maiti, A., Brown, R. E., Corn, P. G., Murthy, R., Ganeshan, D., Tsimberidou, A. M., & Subbiah, V. (2015) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2015.11.004 · Cited by 2
Value of constitutional polymorphisms gene р53 at patients with non-Hodgkin’s lymphomas
Pospelova, T. I., Voyevoda, M. I., Voropayeva, Y. N., Belyavskaya, V. A., Kovynev, I. B., & Валерьевна, Б. О. (2008) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2008-0-56-63 · Cited by 1
Chemoresistance, Dormancy and Recurrence in Platinum Drug Therapy of Ovarian Cancers
Kalir, T., & Kohtz, D. S. (2014) · Springer eBooks · doi:10.1007/978-94-017-9325-4_7 · Cited by 1
Chelakova, Y. A., Dolgikh, О. V., & Alekseev, V. B. (2022) · Advances in health sciences research/Advances in Health Sciences Research · doi:10.2991/ahsr.k.220103.006 · Cited by 1
“An assessment of the state of the immune system, its cellular and humoral parts should be used to diagnose early health disorders in industrial workers in order to prevent a reduction in the working period, disability, and deaths [11, 12].”
Effects of Amifostine on Apoptosis, Cell Cycle and Cytoprotection of Human Colon Cancer Cell Lines
Lee, E. J. (2023) · Journal of Experimental & Biomedical Sciences/Biomedical Science Letters · doi:10.15616/bsl.2023.29.4.287 · Cited by 1
The influence of isoprivet on neutrophil secretory action in the course of BRD in calves
Wessely‐Szponder, J., & Kloc, K. (2010) · Electronic Journal of Polish Agricultural Universities. Series Veterinary Medicine · Cited by 1
Apoptosis in Colorectal Tumorigenesis and Chemotherapy
Yang, S. Y., Sales, K. M., & Winslet, M. C. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9597-9_4 · Cited by 1
Oncogenes and Tumor Suppressor Genes in Therapeutic Resistance
Rak, J. W., Coomber, B. L., & Yu, J. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-035-5_4 · Cited by 1
p53 Inhibitors as Cancer Sensitizing Agents
Maina, F., & Dono, R. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-474-2_12 · Cited by 1
“For example, human colon carcinoma and fibrosarcoma cells are more sensitive to DNA-damaging agents in the absence of p53, with a marked increase in the number of cells undergoing mitotic catastrophe [83, 85–87].”
BackgroundThe p53 Transcription Factor as Therapeutic Target in Cancer
Asker, C., Bykov, V. J. N., Méndez‐Vidal, C., Selivanova, G., Wilhelm, M., & Wiman, K. G. (2004) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-18932-6_7 · Cited by 1
Prognostic factors in colon cancer
Sjo, O. H. (2012) · NORA - Norwegian Open Research Archives · Cited by 1
Anticancer activity of cepharanthine on non-small cell lung cancer cells
Detpichai, Y., & Wonganan, P. (2020) · Chula Digiverse · doi:10.58837/chula.the.2020.380 · Cited by 1
Modeling wild type and mutant p53 in telomerase-immortalized human cellsPreprint
Miciak, J. J., & Bunz, F. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.22.546141 · Cited by 1
Self-citationCharacterization of the BRAF interactome identifies BRAF V600E <=>TP53 interaction in melanomaPreprint
O’Toole, K. T., Martinez, A., Murphy, B., Proveyeka, A., Fort, G., Al-Sudani, F., Boggaram, S. S., Paine, E. L., Baral, D., Andersen, J. L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.20.660711 · Cited by 1
Huang, Z., Luo, S., Wang, Z., Zhang, Z., Jiang, B., Nie, Q. H., & Zhang, J. (2025) · eLife · doi:10.7554/elife.100623.2 · Cited by 2
P53 Links Tumor Development to Cancer Therapy
Hemann, M. T., & Lowe, S. W. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_15 · Cited by 2
“However, p53 status is not a universal predictor of treatment response, in part because not all drugs absolutely require p53 for their apoptotic function (Herr and Debatin, 2001) and, in some settings, p53 loss can enhance drug-induced cell death ( Bunz et al., 1999 ).”
BackgroundInvestigation of the anti-breast cancer efficacy and mechanisms of disulfiram
Liu, P. (2015) · Wolverhampton Intellectual Repository and E-Theses (University of Wolverhampton) · Cited by 1
Aroun, A. (2010) · The University of Bath Online Publications Store (The University of Bath) · Cited by 1
Radiation and Altering Clinical Pharmacology
Smart, D. D., & Camphausen, K. A. (2013) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-9135-4_27
Functional networks of events that modulate phenotypic manifestation of cancer
Thiagalingam, S. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9780511979811.012
Caspase Deficiency: Involvement in Breast Carcinogenesis and Resistance
Yang, X. (2000) · Defense Technical Information Center (DTIC) · doi:10.21236/ada390949
Der Stellenwert der Targeted-Therapie beim Hodentumor
Martinschek, A., Ruf, C. G., Sparwasser, C., & Schmelz, H. (2008) · Der Urologe · doi:10.1007/s00120-008-1750-1
Tumor Markers of Neo-Adjuvant Chemo-Radiation Response in Rectal Cancer
Jacintha, N., Clare, M., & John, V. (2011) · InTech eBooks · doi:10.5772/28095
Montaner, B. (2001) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Efficacy and Mechanistic Evaluation of Tic10, A Novel Antitumor Agent
Allen, J. E. (2012) · ScholarlyCommons (University of Pennsylvania)
Multiple modes of Mdmx regulation affect p53 activation
Gilkes, D. M. (2008) · Digital Commons - University of South Florida (University of South Florida)
Thottassery, J. V., Westbrook, L., Someya, H., & Parker, W. B. (2006) · Cancer Research
Cyclin-Dependent Kinase Inhibitors in Combination Chemotherapy
Shah, M. A., & Schwartz, G. K. (2005) · Humana Press eBooks · doi:10.1385/1-59259-864-1:027
Effect of MMR status and growth rate of colon carcinoma cells in response to 5-fluorouracil
Choudhary, B. (2011) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-8794
Using GEMMs to investigate novel therapeutic strategies for colorectal cancer
Raja, M. (2013) · ORCA Online Research @Cardiff (Cardiff University)
Bedeutung des FGFR4 Polymorphismus in der Pathogenese und Progression von Tumorerkrankungen
Bergmann, C. (2007) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.6379
Analysis of stem cell genome stability and cancer-associated developmental programmes
Aizeer, K. I. (2011) · Bangor University Research Portal (Bangor University)
Interactions Between Myc- and Cyclin-Dependent Kinase Inhibitors in Cancer
Maclean, K. H., & Cleveland, J. L. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-221-2_12
Role of ATP for cytokine-induced murine hepatotoxicity
Latta, M. R. (2003) · KOPS (University of Konstanz)
Nuclear Factor Kappa B Pathway and human cancer therapeutics
Guo, X. (2009) · OpenGrey (Institut de l'Information Scientifique et Technique)
Is it Possible to Predict Benefit from 5FU Adjuvant Therapy in Stage III Colon Cancer Patients?
Bonin, S. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.06.011
“The response to individual drugs is determined by which of these 2 functions is paramount and for 5- FU the apoptotic effect is predominant (Bunz et al., 1999).”
BackgroundInfluentialAnalysis of p53 and c-MYC, two key transcription factors involved in tumorigenesis
Jung, P. (2008) · doi:10.5282/edoc.10559 · Cited by 1
Cals, L., Maille, N., Sohn, C., Tchiknavorian, X., & Poirot, F. (2005) · ONCOLOGIE · doi:10.1007/s10269-005-0290-1
Dissecting the molecular basis of chemosensitivity
Bustin, S. A. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01611-1
CASPASE-3 PROMOTES CELL PROLIFERATION AND INHIBITS DNA-DAMAGE INDUCED NECROSIS IN COLORECTAL CANCER
Brown, M. F. (2013) · D-Scholarship@Pitt (University of Pittsburgh)
Lee, K., & Daoud, S. S. (2009) · The Open Proteomics Journal · doi:10.2174/1875039700902010030
“In contrast, in colon cancer and embryonic fibroblast cells, increased sensitivity to chemotherapeutic agents is associated with the lack of p21 [17,18].”
BackgroundMethodInfluentialThe Role of Genomic Instabilities in Affecting Treatment Responses of Colorectal Cancer
Ricciardiello, L., & Bazzoli, F. (2002) · Digestive Diseases · doi:10.1159/000063158
Hightower, M., Klem, J., Socinski, M. A., Belani, C. P., & Jain, V. K. (2003) · Clinical Lung Cancer · doi:10.1016/s1525-7304(11)70301-1
Adjuvant Treatment and Predictors of Response in Colon Cancer
Aldoss, I. T., & Iqbal, S. (2011) · Seminars in Colon and Rectal Surgery · doi:10.1053/j.scrs.2010.12.015
Un médicament pour un individu
Beaune, P. H. (2002) · médecine/sciences · doi:10.1051/medsci/2002184389
“Les mutations du gène p53 dans les tumeurs modifient la réponse au traitement et en particulier à la chimiothérapie [4], les mutations du gène de l’enzyme de conversion modifient la réponse aux inhibiteurs de cette enzyme et celles du gène des canaux potassiques peuvent être responsables de syndrome du QT long, d’aryt…”
BackgroundMetabolic Regulation and Anticancer Drug Resistance in the Yeast Saccharomyces cerevisiae
Carlsson, M. J. L. (2014) · Epsilon Open Archive (Sveriges lantbruksuniversitet biblioteket (Swedish University of Agricultural Sciences)) · Cited by 1
p90 and UHRF1, Two Novel Regulators of the p53 Signaling Pathway
Dai, C. (2014) · doi:10.7916/d8sq8xcj
“To test this hypothesis, we performed RNAi-mediated inactivation of UHRF1 in HCT116 cells followed by treatment with the 5-fluorouracil (5-FU) antimetabolite that strongly activates p53 and induces p53-dependent growth arrest and apoptosis in HCT116 [281].”
MethodCell Cycle Regulators as Targets of Anticancer Therapy
Blagosklonny, M. V. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-401-6_10
An investigation of p53’s differential activation of cell cycle arrest and apoptosis
Zhang, Y. (2008) · eSpace (Curtin University)
Self-citationA Genomic Approach to the Treatment of Breast Cancer
Chin, K., Toppmeyer, D., Kearney, T. J., REISS, M., Lattime, E. C., & Hait, W. N. (2002) · Elsevier eBooks · doi:10.1016/b978-012437551-2/50026-4
Role of P53 and Bcl-2 in Advanced Rectal Carcinomas Treated with Adjuvant Therapy
Piperno, G., Cosimelli, M., Donnorso, R. P., Mancini, R., Buglioni, S., Novelli, F., Sperduti, I., Zerbini, V., Garufi, C., & Mottolese, M. (2004) · Journal of Chemotherapy · doi:10.1080/1120009x.2004.11782374
Prognostic biomarkers in colorectal cancer with emphasis on microRNA
Schee, K. (2012) · NVA (Nasjonalt vitenarkiv)
Senescence Regulation in Cancer Therapy
Rebbaa, A. (2008) · CRC Press eBooks · doi:10.3109/9781420020502-16
Yu, J., & Zhang, L. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9780511979811.017
Pozzi, M. (2011) · Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) · doi:10.13130/pozzi-marco_phd2011-01-17
Amiss, A. S. (2016) · Otago University Research Archive (University of Otago)
Role of p53 in Apoptosis and Cancer Therapy
Daloii, M. R. N., & Abdollahzade, R. (2014) · مجله علمی پژوهشی افق دانش · Cited by 1
Kruszewski, W. J., Rzepko, R., Warężak, C., Zieliński, J., Jastrzębski, T., Kopacz, A., & Jaśkiewicz, K. (1970) · Nowotwory Journal of Oncology
The Role of FOXO3 in Mechanisms of Doxorubicin Resistance in Hepatocellular Carcinoma
Cox, J. (2016) · KU ScholarWorks (The University of Kansas)
Metadata
- Authors
- Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B.
- Affiliations
- Howard Hughes Medical Institute (US)
- Georgetown University (US)
- Johns Hopkins University (US)
- Corresponding author
- Vogelstein, Bert
- Venue
- Journal of Clinical Investigation
- Published
- 1999-08-01
- Volume
- 104
- Issue
- 3
- Pages
- 263-269
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC408422
- OpenAlex
- W1982097971
- Cited by
- 1,044
- References
- 33
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 17 · 2023: 26 · 2022: 23 · 2021: 19 · 2020: 27 · 2019: 26 · 2018: 25 · 2017: 24 · 2016: 36 · 2015: 32 · 2014: 35 · 2013: 43 · 2012: 38
- FWCI
- 22.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Foundation for Cancer Research
- Johns Hopkins University
- National Institutes of Health
- National Cancer Institute (CA 57345, R01CA057345, P50CA062924, R37CA057345, CA 62924)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- p53, p53 deficiency, chemoresistance, 5-fluorouracil, antimetabolite resistance, p21, cyclin-dependent kinase inhibitors, DNA-damaging agents, chemosensitization, colon cancer, colorectal cancer, RNA metabolism, drug response
- MeSH terms
- Animals, Antineoplastic Agents, Colonic Neoplasms, DNA Damage, Doxorubicin, Fluorouracil, Humans, Mice, Nude, Neoplasm Transplantation, Transplantation, Heterologous, Tumor Cells, Cultured, Genes, p53, Tumor Suppressor Protein p53, Cyclins, Apoptosis, Gene Deletion, Drug Resistance, Neoplasm, Cyclin-Dependent Kinase Inhibitor p21, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.